Anthem Biosciences Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a standalone net profit of INR 6,705.64 million for the year, marking a 32.5% increase from INR 5,061.88 million in the previous year. Revenue from operations for the year stood at INR 20,893.12 million, compared to INR 18,406.49 million in FY25.

For the quarter ended March 31, 2026, the company recorded a standalone net profit of INR 2,116.65 million. Revenue from operations for the quarter was INR 5,825.01 million. The Board approved the audited standalone and consolidated financial results prepared in accordance with the Indian Accounting Standards (Ind-AS).

Dividend Declaration

The Board of Directors recommended a final dividend of INR 2.00 per equity share of face value INR 2.00 each for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting. The record date for the purpose of determining eligibility has been fixed as Friday, June 26, 2026.

Corporate Actions

The Board approved the allotment of 14,81,250 equity shares to eligible employees upon exercise of options under the Anthem Employee Stock Option Plan 2024. Consequently, the paid-up equity share capital has increased to INR 1,12,63,90,202. Additionally, the Board approved convening the 20th Annual General Meeting on Wednesday, July 22, 2026.

The Board also recommended the continuation of Mr. Ravikant Uppal as a Non-Executive Independent Director and the re-appointment of Mr. Ravindra Chandrappa as Whole Time Director, subject to shareholder approval.

The statutory auditors, M/s. K. P. Rao & Co., issued an unmodified opinion on the audited standalone and consolidated financial results. The company also re-appointed M/s. BPU & Co. as internal auditors for the financial year 2026-2027.

Anthem Biosciences Limited's Board of Directors convened on April 22, 2026, from 2:30 PM to 3:32 PM IST, approving two significant corporate matters requiring regulatory disclosure under SEBI guidelines. The company formally notified BSE and NSE about the appointment of new statutory auditors and approval of an upside sharing arrangement involving substantial financial implications.

Statutory Auditor Transition

The Board approved the appointment of new statutory auditors following the Audit Committee's recommendation. The current auditors, K.P. Rao & Co., Chartered Accountants, will complete their tenure at the conclusion of the twentieth Annual General Meeting scheduled for financial year 2026-2027.

The incoming audit firm, established in 1949 with its registered office in Kolkata, operates across key Indian cities and maintains a network of affiliated firms providing audit and assurance services to diverse market segments including Industrial, Infrastructure, Consumer Products, Financial Services, Technology, Media and Entertainment, Telecommunications and Professional Services.

Upside Sharing Arrangement Approval

The Board approved an existing upside sharing arrangement under Regulation 26(6) of SEBI LODR, recommending it for public shareholder approval through an ordinary resolution. This arrangement stems from the Shareholders' Agreement dated March 01, 2021, as amended by the Waiver-cum-Amendment Agreement dated December 30, 2024.

The arrangement involves sharing returns from Viridity Tone LLP's post-listing equity share divestment when the investor's returns exceed specific thresholds. The upside sharing mechanism activates when returns surpass the higher of 25% of the invested amount or 2 times the original investment.

Recent Transaction Impact

The upside sharing arrangement became operational following Viridity Tone LLP's significant divestment on March 09, 2026. The transaction involved the sale of equity shares, generating substantial proceeds and triggering the upside sharing mechanism.

Regulatory Compliance and Documentation

Both matters align with SEBI's listing obligations and disclosure requirements. The company has ensured comprehensive documentation with the Shareholders' Agreement and Waiver-cum-Amendment Agreement available on the company's investor website. The salient terms were previously disclosed in the July 16, 2025 prospectus under "History and Certain Corporate Matters."

Appropriate disclosures regarding the upside sharing arrangement will be included in the notice for the twentieth Annual General Meeting. The company secretary Divya Prasad signed the regulatory filing, confirming compliance with all applicable regulations and maintaining transparency with stakeholders and regulatory authorities.